276 related articles for article (PubMed ID: 30877775)
1. Aspirin Triggered Resolvin D1 reduces inflammation and restores saliva secretion in a Sjögren's syndrome mouse model.
Dean S; Wang CS; Nam K; Maruyama CL; Trump BG; Baker OJ
Rheumatology (Oxford); 2019 Jul; 58(7):1285-1292. PubMed ID: 30877775
[TBL] [Abstract][Full Text] [Related]
2. Predictive modeling of aspirin-triggered resolvin D1 pharmacokinetics for the study of Sjögren's syndrome.
Yellepeddi VK; Baker OJ
Clin Exp Dent Res; 2020 Apr; 6(2):225-235. PubMed ID: 32250566
[TBL] [Abstract][Full Text] [Related]
3. Sex-mediated elevation of the specialized pro-resolving lipid mediator levels in a Sjögren's syndrome mouse model.
Parashar K; Schulte F; Hardt M; Baker OJ
FASEB J; 2020 Jun; 34(6):7733-7744. PubMed ID: 32277856
[TBL] [Abstract][Full Text] [Related]
4. AT-RvD1 Promotes Resolution of Inflammation in NOD/ShiLtJ mice.
Wang CS; Maruyama CL; Easley JT; Trump BG; Baker OJ
Sci Rep; 2017 Mar; 7():45525. PubMed ID: 28361884
[TBL] [Abstract][Full Text] [Related]
5. AT-RvD1 combined with DEX is highly effective in treating TNF-α-mediated disruption of the salivary gland epithelium.
Easley JT; Maruyama CL; Wang CS; Baker OJ
Physiol Rep; 2016 Oct; 4(19):. PubMed ID: 27694530
[TBL] [Abstract][Full Text] [Related]
6. Specialized pro-resolving receptors are expressed in salivary glands with Sjögren's syndrome.
Dos Santos HT; Nam K; Maslow F; Trump B; Baker OJ
Ann Diagn Pathol; 2022 Feb; 56():151865. PubMed ID: 34847389
[TBL] [Abstract][Full Text] [Related]
7. Expression of resolvin D1 biosynthetic pathways in salivary epithelium.
Leigh NJ; Nelson JW; Mellas RE; Aguirre A; Baker OJ
J Dent Res; 2014 Mar; 93(3):300-5. PubMed ID: 24389810
[TBL] [Abstract][Full Text] [Related]
8. Aspirin-Triggered Resolvin D1 Versus Dexamethasone in the Treatment of Sjögren's Syndrome-Like NOD/ShiLtJ Mice - A Pilot Study.
Easley JT; Nelson JW; Mellas RE; Sommakia S; Wu C; Trump B; Baker OJ
J Rheum Dis Treat; 2015; 1(4):. PubMed ID: 27110599
[TBL] [Abstract][Full Text] [Related]
9. Bufotalin ameliorates experimental Sjögren's syndrome development by inhibiting Th17 generation.
Huang Y; Yang G; Fei J; Wu Y; Yan J
Naunyn Schmiedebergs Arch Pharmacol; 2020 Oct; 393(10):1977-1985. PubMed ID: 31950221
[TBL] [Abstract][Full Text] [Related]
10. A combination treatment of low-dose dexamethasone and aspirin-triggered resolvin D1 reduces Sjögren syndrome-like features in a mouse model.
Dos Santos HT; Maslow F; Nam K; Trump B; Weisman GA; Baker OJ
JADA Found Sci; 2023; 2():. PubMed ID: 37622089
[TBL] [Abstract][Full Text] [Related]
11. ALX/FPR2 receptor for RvD1 is expressed and functional in salivary glands.
Nelson JW; Leigh NJ; Mellas RE; McCall AD; Aguirre A; Baker OJ
Am J Physiol Cell Physiol; 2014 Jan; 306(2):C178-85. PubMed ID: 24259417
[TBL] [Abstract][Full Text] [Related]
12. Predicting Resolvin D1 Pharmacokinetics in Humans with Physiologically-Based Pharmacokinetic Modeling.
Yellepeddi VK; Parashar K; Dean SM; Watt KM; Constance JE; Baker OJ
Clin Transl Sci; 2021 Mar; 14(2):683-691. PubMed ID: 33202089
[TBL] [Abstract][Full Text] [Related]
13. Current experimental methods to investigate the impact of specialized pro-resolving lipid mediators on Sjögren's syndrome.
Dos Santos HT; Nam K; Gil D; Yellepeddi V; Baker OJ
Front Immunol; 2022; 13():1094278. PubMed ID: 36713415
[TBL] [Abstract][Full Text] [Related]
14. Metformin improves salivary gland inflammation and hypofunction in murine Sjögren's syndrome.
Kim JW; Kim SM; Park JS; Hwang SH; Choi J; Jung KA; Ryu JG; Lee SY; Kwok SK; Cho ML; Park SH
Arthritis Res Ther; 2019 Jun; 21(1):136. PubMed ID: 31164166
[TBL] [Abstract][Full Text] [Related]
15. An immunohistochemistry-based study on aquaporin (AQP)-1, 3, 4, 5 and 8 in the parotid glands, submandibular glands and sublingual glands of Sjögren's syndrome mouse models chronically administered cevimeline.
Nakamura M; Saga T; Watanabe K; Takahashi N; Tabira Y; Kusukawa J; Yamaki K
Kurume Med J; 2013; 60(1):7-19. PubMed ID: 23925155
[TBL] [Abstract][Full Text] [Related]
16. Impaired salivary gland function in NOD mice: association with changes in cytokine profile but not with histopathologic changes in the salivary gland.
Jonsson MV; Delaleu N; Brokstad KA; Berggreen E; Skarstein K
Arthritis Rheum; 2006 Jul; 54(7):2300-5. PubMed ID: 16802370
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal Stem Cells Extract (MSCsE)-Based Therapy Alleviates Xerostomia and Keratoconjunctivitis Sicca in Sjogren's Syndrome-Like Disease.
Abughanam G; Elkashty OA; Liu Y; Bakkar MO; Tran SD
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31557796
[TBL] [Abstract][Full Text] [Related]
18. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice.
Nguyen CQ; Hu MH; Li Y; Stewart C; Peck AB
Arthritis Rheum; 2008 Mar; 58(3):734-43. PubMed ID: 18311793
[TBL] [Abstract][Full Text] [Related]
19. Resolvin D1 prevents TNF-α-mediated disruption of salivary epithelial formation.
Odusanwo O; Chinthamani S; McCall A; Duffey ME; Baker OJ
Am J Physiol Cell Physiol; 2012 May; 302(9):C1331-45. PubMed ID: 22237406
[TBL] [Abstract][Full Text] [Related]
20. Disruption of endothelial barrier function is linked with hyposecretion and lymphocytic infiltration in salivary glands of Sjögren's syndrome.
Cong X; Zhang XM; Zhang Y; Wei T; He QH; Zhang LW; Hua H; Lee SW; Park K; Yu GY; Wu LL
Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3154-3163. PubMed ID: 29981359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
